Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia.

The ability of 4-color flow cytometry (FC) to help identify myelodysplastic syndromes (MDSs) was evaluated in 124 bone marrow aspirates from unselected patients with unexplained cytopenias and/or monocytosis. The morphologic features of bone marrow aspirate smears were correlated with FC and cytogenetic findings blindly, and patterns of antigen expression were compared with patterns seen in nonneoplastic and normal marrow specimens. Of 124 cases, 58 (46.7%) had definitive FC abnormalities ("flow-abnormal"), 19 cases (15.3%) had mild FC abnormalities of indeterminate significance, and 47 cases (37.9%) had essentially normal FC. Highly significant differences were identified between the flow-abnormal group and other groups in mean myeloid blast percentages and numbers of abnormal antigens expressed, even when the analysis was limited to cases with fewer than 5% myeloid blasts. Strikingly, flow-abnormal cases constituted 50 (89%) of the 56 morphologically abnormal cases and 31 (94%) of the 33 cytogenetically abnormal cases, demonstrating the strong concordance of FC-identified antigenic abnormalities with morphologic features and cytogenetics in the evaluation of patients with unexplained cytopenias.

[1]  A. Bagg,et al.  Peripheral blood MDS score: A new flow cytometric tool for the diagnosis of myelodysplastic syndromes , 2005, Cytometry. Part B, Clinical cytometry.

[2]  B. Wood,et al.  Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders. , 2003, American journal of clinical pathology.

[3]  B. Wood,et al.  Using 4-color flow cytometry to identify abnormal myeloid populations. , 2003, Archives of pathology & laboratory medicine.

[4]  Juan Du,et al.  Evidence for expression of early myeloid antigens in mature, non‐blast myeloid cells in myelodysplasia , 2003, American journal of hematology.

[5]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[6]  H. Deeg,et al.  Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. , 2003, Blood.

[7]  M. Mori,et al.  Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. , 2002, Blood.

[8]  Yvan Cornet,et al.  Immunophenotypic clustering of myelodysplastic syndromes. , 2002, Blood.

[9]  C. Vasselon,et al.  Expression and prognostic significance of Bcl‐2 family proteins in myelodysplastic syndromes , 2002, American journal of hematology.

[10]  D C Arthur,et al.  Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. , 2001, Blood.

[11]  A. Dobrovic,et al.  Loss of red cell A, B, and H antigens is frequent in myeloid malignancies. , 2001, Blood.

[12]  R. Ohno,et al.  Decreased amount of mpl and reduced expression of glycoprotein IIb/IIIa and glycoprotein Ib on platelets from patients with refractory anemia: analysis by a non‐isotopic quantitative ligand binding assay and immunofluorescence , 2001, European journal of haematology.

[13]  Bengt Fadeel,et al.  Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases , 2001, British journal of haematology.

[14]  R. Hutchison,et al.  Apoptotic index by Annexin V flow cytometry: adjunct to morphologic and cytogenetic diagnosis of myelodysplastic syndromes. , 2001, Cytometry.

[15]  O. Sordet,et al.  Expression and activity of caspases 1 and 3 in myelodysplastic syndromes , 2000, Leukemia.

[16]  T. Matthes,et al.  Increased apoptosis in acquired sideroblastic anaemia , 2000, British journal of haematology.

[17]  G. Mufti,et al.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.

[18]  R. Cleveland,et al.  Decreased CD10-positive mature granulocytes in bone marrow from patients with myelodysplastic syndrome. , 2000, Archives of pathology & laboratory medicine.

[19]  K. Ohyashiki,et al.  Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia. , 2000, Leukemia research.

[20]  P. Hokland,et al.  Flow cytometric identification of myeloid disorders by asynchronous expression of the CD14 and CD66 antigens , 1998, European journal of haematology.

[21]  S Dilly,et al.  Bone marrow pathology , 1949 .

[22]  K. Iwabuchi,et al.  Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes , 1997, British journal of haematology.

[23]  S. Bigner,et al.  Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. , 1997, American journal of clinical pathology.

[24]  M. Vadas,et al.  Neutrophils activated by granulocyte-macrophage colony-stimulating factor express receptors for interleukin-3 which mediate class II expression. , 1995, Blood.

[25]  M. Loken,et al.  CD45 Gating for Routine Flow Cytometric Analysis of Human Bone Marrow Specimens , 1993, Annals of the New York Academy of Sciences.

[26]  M. Pierotti,et al.  bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. , 1992, Blood.

[27]  L. Terstappen,et al.  Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. , 1990, Leukemia.

[28]  L. Terstappen,et al.  Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. , 1990, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[29]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[30]  B. Bain,et al.  Bone Marrow Pathology , 1949 .

[31]  A. Órfão,et al.  Immunophenotypic analysis of myelodysplastic syndromes. , 2003, Haematologica.

[32]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[33]  M. Elghetany,et al.  Surface marker abnormalities in myelodysplastic syndromes. , 1998, Haematologica.

[34]  J. Holland,et al.  Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome. , 1996, Journal of clinical & laboratory immunology.